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ABSTRACT 
CAPECIT ABINE INDUCED HAND AND FOOT SYNDROME AND THE 
REPRODUCIBILITY OF FRICTION SKIN 
by Rodney Allen Schenck 
May 2012 
In 2008, a 62 year old male was detained by United States Customs and 
Immigration officials when attempting to enter the United States because his fingerprints 
were not detectable. It was later reported by his medical doctor in Singapore that the 
individual suffered from Hand and Foot Syndrome (palmar-plantar erythrodysaesthesia) 
as a result of his cancer treatment of capecitabine (N4-pentyloxycarbonyl-5-deoxy-5-
fluorocytidine) which causes interruptions to the normal growth of keratinocytes in the 
friction skin. Capecitabine is a recently developed, orally administered fluoropyrimidine 
prodrug designed to generate 5-fluorouracil through a three-step enzymatic process 
giving it antineoplastic properties to combat cancerous tumor growth in a number of 
different cancers, including adjuvant colon cancer, metastatic colorectal cancer, and 
metastatic breast cancer. This study consisted of a 253-day evaluation of the 
physiological effects to the friction ridge skin from an individual undergoing capecitabine 
chemotherapy treatment. The results indicate the quality of the friction ridge skin 
impressions decreased by 32% and to a degree which may impair the ability to positively 
identify individuals using friction skin impressions alone while undergoing this type of 
treatment and experiencing hand and foot syndrome. Following cessation of capecitabine 
treatment, normal growth of keratinocytes resumed returning the skin to a normal state 
11 
with no indication of damage thus demonstrating the persistency of the friction ridge skin 
despite the temporary toxicity of capecitabine. 
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CHAPTER I 
INTRODUCTION 
Friction Ridge Skin 
1 
Friction ridge skin is a specialized type of skin found primarily on the palmar 
surface of the hands and the plantar surface of the feet. This special layer of skin is 
comprised of two anatomical layers, the epidermis and the dermis. The layer of primary 
concern for means of personal identification is the epidermis as it is comprised of a series 
of furrows and ridges with embedded eccerine sweat glands. Although eccerine sweat 
glands are found in skin throughout the body, they are found in the highest concentrations 
in the friction skin. As a primary function, these eccerine sweat glands secrete sweat and 
exude waste covering the friction skin with a contaminate or "matrix." This matrix, when 
in contact with an adequate surface or substrate, can be transferred to that substrate in the 
same unique formation as the friction ridges on the fingers resulting in what is commonly 
referred to as a latent fingerprint or latent impression. 
Fingerprints take on three general patterns: the arch, the loop, and the whorl. In 
the arch pattern, ridges enter one side of the pattern area, make a slight rise in the center 
and exit out the other side. In the loop pattern, ridges enter one side of the pattern area, 
loop around to form a recurve, and exit back out the same side. Whorls can take on many 
appearances but generally take on a "bull's eye" appearance. Within the pattern areas of 
loops and whorls are focal points called cores and deltas. The core is the approximate 
center of the pattern area. The delta is the area at which the ridges diverge or form a Y 
shape (Enforcement) (Figure 1). The recognition, development and preservation along 
with careful analysis, comparison and evaluation of the features captured within the 
transferred matrix is what allows a trained individual to render an opinion if 
individualization. 
Core 
Delta 
Arch Loop 
Figure 1. Fingerprint Patterns and Focal Points. 
2 
Friction ridge skin has been used as a means of personal identification throughout 
many cultures for thousands of years. Evidence shows the use of friction ridge skin as 
proof of an individual 's identity in China dating as far back as 300 B.C. However, the 
modem day use of friction ridge skin as a means of personal identification has been used 
for well over a century with multiple purposes such as identity verification and forensic 
identification. International travel ports rely heavily on the use of fingerprints to ensure 
foreign visitors produce proper forms of identification and ensure these visitors do not 
pose a potential security threat. U.S. Customs and Border Patrol agents have the ability to 
reference a multitude of digitally captured biometric information databases in an attempt 
to conduct immediate and thorough security searches. Biometric information is ca~tured 
and stored from individuals on a daily basis. Facial images, iris scans, and fingerprints 
are three of the primary means of biometrically enrolling an individual for later retrieval. 
While facial and iris recognition software are still somewhat in their infancy stages of 
development, the use of fingerprint identification has proven to be the mainstay of 
identification due to the low cost and quick results. One of the more frequently employed 
techniques to enable personal identification is through the use of fingerprints via an 
Automated Fingerprint Identification System (AFIS). The use of fingerprints as a means 
of personal identification is dependent upon the reproducibility of the unique 
arrangements of friction ridge skin on the surface of the fingers. Due to the high volume 
of visitors processed each day in these international travel ports, officials rely heavily on 
automated systems to record and compare the fingerprints of foreign visitors prior to 
entry into the United States. Failure of the friction ridge skin to record properly will 
prevent this routine security process from occurring bringing into question a potential 
threat to national security. 
Friction Ridge Skin Alteration 
3 
The idea behind using fingerprints as a means of personal identification is 
established on two basic premises: uniqueness and permanence. The first individual to 
recognize that friction skin was unique was German anatomist J.C. A. Mayer around the 
year 1788 while German anthropologist Hermann Welcker was the first to establish 
permanency in 1856. (U.S. Department of Justice, 2011). 
Since this time, numerous attempts have been made by nefarious individuals to 
disguise or alter the unique arrangements of friction skin on the tips of the fingers in an 
attempt to avoid detection and/or fool automated systems. Some of the more notable 
attempts include that by the infamous mobster John Dillinger who used acid in an attempt 
to dissolve several layers of the epidermis (Figure 2). 
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-----------------------------------LE:F"T HAND 
7. Index Finger 8. Middle Finger 0. Ring Finger 
Figure 2. Postmortem record fingerprints of DILLINGER depicting acid damage 
(Wertheim, 2002). 
Other techniques involved the use of abrasive materials to brush away the friction 
ridges, the graphing of other friction ridge skin (Figure 3) or non-friction ridge skin 
(Figure 4) transplantation onto the tips of the fingers and a more recent "Z-flap" surgical 
technique designed to alter the pattern on the surface of the finger (Figure 5). 
Figure 3. Transplantation of other Friction Ridge Skin onto the tips of the fingers. 
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Figure 4. Transplantation of non-friction ridge skin onto the tips of the fingers. 
Figure 5. Right Thumb before (1999) and after (2009) Z-Flap alteration. 
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Figure 6. Diagram depicting method of Z-Flap alteration. 
It is important to note here that all past attempts have been via either a deliberate 
topical application or physical alteration of the friction skin. Of more important notice is 
that despite the numerous attempts over the last 100 years, none have been successful. 
Recently, the author of this paper had the opportunity to observe the biochemical changes 
in friction ridge skin through an internal chemical application as an unintentional side 
effect of chemotherapy treatment medication. As a result, a study was conducted and the 
data referenced within this paper. 
The focus of this study is two-fold: 1) To understand the association between 
capecitabine induced HFS and the reproducibility of friction ridge skin for forensic or 
other comparative purposes, and 2) To reinforce the basic premise behind friction ridge 
identification regarding permanency despite biochemical alteration. This will be 
accomplished by analyzing the previously recorded quality of record fingerprint 
impressions obtained from an individual diagnosed with metastatic breast cancer during 
the entire course of capecitabine treatment. While the changes in quality of captured ridge 
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detail throughout the course of chemotherapy treatment is the main scope of this project; 
the reemphasis of one of the key premises permanency behind friction ridge identification 
is a major contribution to the field of forensic science, particularly to the friction ridge 
identification discipline. The permanency of friction ridge skin after biochemical induced 
changes has not previously been explored in the literature available to the author. 
CHAPTER II 
LITERATURE REVIEW 
The Skin 
Friction ridge skin, like all skin on the human body has two outer layers: the 
epidermis and the dermis (Figure 7). The epidermis is the outermost layer of skin and is 
Spinou5 
Figure 7. Dermis and Epidermis. 
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made up of several layers of skin cells, including the horny layer which is composed of 
dead skin cells at the skin surface. The dermis is made up of loose connective tissues and 
houses various blood vessels, tactile nerves, and glands, including sweat glands. 
The lowest layer, or basal layer, of the epidermis is where new skin cells are 
generated (Ashbaugh, 1999) (Figure 8). Over the course of 30-45 days, as new cells are 
Figure 8. Cellular layers of the Epidermis. 
generated, older cells migrate toward the skin surface. During the migration, the cells 
change in structure, gradually dehydrating and dying off as they reach the topmost or 
horny layer. Once at the horny layer, the dead skin cells will eventually be sloughed off, 
or shed, to make way for the newer cells. (Enforcement). 
9 
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The Problem 
It was reported in a letter published in Annals of Oncology in ear_ly 2009 by Dr. · 
Eng-Huat Tan, a Cancer Specialist in the Medical Oncology Department of the National 
Cancer Center in Singapore, that a 62 year old male diagnosed with :metastatic 
nasopharyngeal carcinoma was detained by the United States cu·stoms at1d Immigration · 
Service in December 2008 (Wong, 2009). This individual, identiffoci as Mr; S., was 
detained while attempting to enter the United States from Singapore because his 
fingerprints were not detectable. After four hours of detainment, officials were satisfied 
that Mr S. did not pose a threat to national security via other means of biometric and 
intelligence data and was released. It was later determined that the inability to detect Mr. 
S.' fingerprints was due to a side effect of his current chemotherapy treatment. Dr. Tan 
reported that following Mr. S. ' previous treatment regimen of a cisplatin-5-fluorouracil 
(5FU) combination, he was administered capecitabine (N4-pentyloxycarbonyl-5-deoxy-
5-fluorocytidine) from July 2005 (1750 mg twice a day, 2 weeks on, 1 week off) as 
maintenance treatment. Upon follow up of his capecitabine treatment, Mr. S was 
diagnosed with grade 2 hand and foot syndrome (HFS), also called palmar-plantar 
erythrodysaesthesia (Wong, 2009) which is histologically characterized as basal 
keratinocyte toxicity causing dyskeratosis (premature keratinization) with pronounced 
eosinophilia (high concentration of white blood cells) in the Stratum Spinosum and 
isolated keratinocyte necrobiosis (cellular death) (Janusch, 2006; Saini, 2007; Surjushe, 
2009). 
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Palmar-Plantar Erthrodysesthesia (PPE) aka Hand and Foot Syndrome (HFS) 
HFS is a distinctive and relatively common toxic reaction related to some 
chemotherapeutic agents that was initially described by Zuehlke in 1974 in association 
with mitone therapy for a hypernephroma (Baack, 1991). Symptomatically, HFS is 
characterized as numbness, dysaesthesia/paraesthesia (unpleasant/abnormal tingling, 
prickling, numbness feeling), erythema (redness of skin), painless swelling or discomfort 
and, in more severe cases; blisters, ulceration, desquamation (peeling of skin), or severe 
pain on the palms of the hands and soles of the feet. Severe cases of HFS can interfere 
with the normal daily activities of patients and is considered the major dose-limiting 
toxicity of capecitabine treatment necessitating dose reduction, treatment interruption, or 
in severe cases of HFS, withdrawal of treatment. It has been well documented that 
treatment interruption followed by dose reduction, if necessary, usually leads to rapid 
reversal of the symptoms with no long-term consequences. (Janusch, 2006; Milano, 
2008). Although not life-threatening, PPE/HFS can develop into a painful and 
debilitating condition that interferes with patients' activities of daily living and quality of 
life. The mainstay of the PPE/HFE management appears to be a dose reduction or 
treatment interruptions coupled with supportive measures to reduce pain and discomfort 
and prevent secondary infections (Viale, 2006). 
Grading systems for PPE/HFS have been established to assess the severity of 
conditions. These tools are instrumental in helping nurses recognize and assess both the 
objective and subjective symptoms of this toxicity and initiate the appropriate 
interventions. The grading systems used for PPE/HFE may vary per institution; however, 
the majority of systems are comprised of three basic categories. Grade 1 PPE/HFE 
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typically involves numbness, dysesthesia/paresthesia, tingling, painless swelling, or 
erythema of the hands and/or feet and basic discomfort that does not disrupt normal 
activities. Patients experiencing Grade 1 symptoms typically maintain their doe level 
during the course of treatment and are monitored closely to see if symptoms worsen. 
Grade 2 PPE/HFE typically involves painful erythema with swelling of the hands and/or 
feet and discomfort affecting daily activities. During the first, second, and third 
appearance of Grade 2 symptoms, capecitabine treatment is typically interrupted until 
symptoms are reduced down to Grade 1. Treatment is typically permanently discontinued 
on the fourth appearance of Grade 2 symptoms with a similar course of action upon the 
onset of Grade 3 PPE/HFS. Grade 3 involves moist desquamation coupled with 
ulceration, blistering, or severe pain of the hands and feet and severe discomfort that 
causes the· patient to be unable to work or perform activities of daily living -(Xeloda 
Prescribing Information, 2005). 
Capecitabine and its Pathogenesis 
Physicans and oncology nurses must continuously update their knowledge on 
current treatments and treatment-related side effects; and they must search for effective 
methods to prevent and/or manage the side effects that develop. Capecitabine is the 
recently developed, orally administered fluoropyrimidine prodrug designed to generate 
5FU through a three step enzymatic process giving it antineoplastic properties to combat 
cancerous tumor growth in a number of different cancers, including adjuvant colon 
cancer, metastatic colorectal cancer, and metastatic breast cancer (Drug Information 
Online; Milano, 2008; Quinney, 2005; Saini, 2007). It should be noted that a number of 
other cancer treatment regimes have been reported to cause HFS. Chemotherapeutic 
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concoctions involving Capecitabine (Xeloda), Cytarabine (Cytosar-U), Floxuridine 
(FUDF), Fluorouracil (5-FU, Adrucil), Idarubicin (Idamycin), Liposomaldoxorubicin 
(Doxil), Doxorubicin (Adriamycin), Sunitinib (Sutent), Sorafenib (Nexavar), Pazopanib 
(Votrient) and Vemurafenib (Zelboraf) are some of the more common producers of HFS. 
However, while HFS is observed at a greater frequency among patients undergoing 
capecitabine treatment as opposed to other treatments; the incidences of diarrhea, 
stomatitis (inflammation of the mouth), nausea/vomiting, alopecia (loss of hair), and 
nutropenia ( decrease in white blood cells in neutrophils) associated with these other 
chemotherapeutic agents is markedly lower. In addition to the .lower inci.dences of these . 
symptoms, the benefit of reduced hospitalization time and associated costs related to 
capecitabine treatment as opposed to other methods has caused capecitabine treatment to 
become a superior treatment regimen for these types of cancers (Quinney, 2005). 
The in vivo three-step enzymatic activation process of capecitabine to 
preferentially target 5FU production in tumor cells begins with its hydrolization by a · 
60kDa carboxylesterase (enzyme) in the liver converting capecitabine to the intermediate 
5-DFCR (5-deoxy-5-fluorocytidine). In the second step 5-DFCR is converted to 5-DFUR 
(5-deoxy-5-fluorouridine) by cytidine deaminase which is an enzyme found in most 
tissues, including tumor tissues. The third step exploits the high concentrations .of the 
enzyme thymidine phosphorylase (TP) in some human carcinomas compared to 
surrounding normal tissues. TP hydrolyzes 5-DFUR to the active drug 5-FU (Chua, Wei, 
Sham, & Au, 2008; Drug Information Online; Milano, 2008). The relative high 
concentration of TP in some human carcinomas acts to preferentially localize the 
continuous exposure of malignant cells to the cytotoxic effects of 5FU while reducing 
exposure to normal tissues thus limiting systemic toxicity (Chua,·Wei, Sham, & Au, 
2008; Milano, 2008). 
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Once 5-FU is generated via the TP enzyme it is further metabolized by both 
normal and tumor cells into 5-fluoro-2 deoxyuridine monophosphate (FdUMP) and 5-
fluorouridine triphosphate (FUTP) which inhibit deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) synthesis causing cell cycle arrest and apoptosis (cell death),· 
thereby combating malignant cell growth by two different mechanisms: (1) FdUMP, in 
the presence of the folate cofactor 5, 10-methylenetetrahydrofolate, bind to thymidylate 
synthase (enzyme) thus inhibiting the formation of thymidylate which is a necessary 
precursor to thymidine triphosphate and essential for DNA synthesis thus inhibiting cell 
division, and (2) FUTP, which is structurally similar but chemically· different to uridine 
triphosphate (a pyrimidine nucleotide necessary for RNA synthesis), is mistakenly .· 
incorporated by nuclear transcription enzymes in place of uridine triphosphate during 
RNA synthesis thus further preventing cell growth (Drug Information Online). 
The exact pathogenesis of capecitabine induced HFS is unknown (Janusch, 2006; 
Milano, 2008; Surjushe, 2009); however, evidence suggests that the same mechanism in 
which capecitabine prevents malignant cell growth is thought to be the cause of 
capecitabine induced HFS exhibiting its cytotoxic effects not only on malignant cells, but 
also on basal keratinocytes. The pathophysiology of PPE/HFS is also not completely 
understood. It has been hypothesized that PPE/HFS is the result of small capillaries in the 
palm of the hands and soles of the feet rupturing under pressure causing small amounts of 
chemotherapeutic drugs to leak into tissues resulting in an inflammatory- type reaction. 
Another theory suggests that chemotherapeutic drugs are eliminated by sweating. 
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Because the hands and feet have an increased number of sweat glands, this theory 
postulates that these areas would be more prone to developing PPE/HFS (Webster-
Gandy, 2007). TP has been found to also be expressed in a much higher concentration in 
friction ridge skin than other surrounding tissues (Milano, 2008) due to its association 
with keratinocyte hyperproliferation (high rate of keratinocyte division) (Schwartz, 
1991 ). Thus, similar to the increased production and accumulation of 5-FU in malignant 
cells due to their higher proliferation rate and increased TP activity, the higher 
proliferation rate of keratinocytes and associated TP activity compared to other normal 
somatic cells (non-friction ridge skin cells) has been suggested to preferentially expose 
keratinocytes to the local cytotoxicity of 5-FU metabolites (Milano, 2008). Furthermore, 
the interrelationship between proliferating keratinocytes and thymidine metabolism has 
been demonstrated by Schwartz et al. ( 1991 ). This suggests that, in addition to nuclear 
transcription errors caused by FUTP, in the absence of thymidine due to the inhibition of 
thymidylate synthase to form thymidylate, proper basal keratinocyte proliferation is 
inhibited thus supporting the histological findings of dyskeratosis (premature 
keratinization) and isolated basal keratinocyte necrobiosis (cellular death) (Janusch, 
2006; Saini, 2007; Surjushe, 2009) as well as the symptomatic desquamation (peeling of 
skin) associated with HFS previously noted. Due to the rapid proliferation rate of basal 
keratinocytes, upon a reduction in dosage or cessation of capecitabine treatment, 
concentrations of 5-FU decrease thus allowing for proper basal keratinocyte proliferation 
to resume resulting in a reversal of HFS related symptoms (Janusch, 2006; Milano, 
2008). 
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The overall incidence of HFS observed with capecitabine·in clinical trials of 
breast or colorectal cancer has been reported to be around 50% with 17% of patients 
reporting a severe form ofHFS (grade 3) (Milano, 2008). Others studies by Hyun-Sook, 
et el report the prevalence of HFS to be as high at 77% with a severe form (grade 3) at 
15.5% (Hyun-Sook, 2009). Because of the high incidence ofHFS associated with 
capecitabine treatment coupled with the favorable chemotherapeutic factors compared to 
other methods for treating these types of cancers, it is suspected that the number of 
patients receiving capecitabine treatment will continue to increase. 
Permanency and Forensic Science 
Fordham Law Review has recognized that fingerprints are permanent by stating 
that fingerprints are contained in the epidermis (the outermost layer of human skin) but 
they are imprinted in, and generated from, the dermis (the thick layer of tissue underlying. 
the epidermis). Thus, a fingerprint will not be destroyed unless damage to the skin 
reaches the dermis. Moreover, fingerprints remain unchanged from infancy until death; 
while they may expand or contract based on the weight of the individual, the pattern 
remains static. This characteristic is known as the permanency factor (Sombat). It has 
also been accepted in high profile court cases such as United States v. Llera Plaza (1998) 
where the court upheld that the government's expert could testify to the permanency and 
uniqueness of fingerprints (Sombat). Even in the controversial 2009 National Academy 
of Science (NAS) report entitled Strengthening Forensic Science in the United States: A 
Path Forward, the harshest of fingerprint critics state that the question is less a matter of 
whether each person's fingerprints are permanent and unique- uniqueness is commonly 
assumed - and more a matter of whether one can determine with adequate reliability that 
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the finger that left an imperfect impression at a crime scene is the same finger that left an 
impression with different imperfections in a file of fingerprints (Council, 2009) 
As displayed in these stated proclamations by some renowned sources, the 
scientific basis of permanency regarding friction ridge skin identification is accepted 
throughout the scientific community. However, all previous research leading to these 
proclamations is based strictly on the idea of regeneration baring a healthy dermis. This 
project will explore the idea of permanency despite biochemical alteration and reinforce 
the premise behind the use of friction skin as a means of personal identification. 
CHAPTER III 
MATERIALS AND METHODS 
Study Information 
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This study was designed to be completed as a case study to evaluate the 
reproducibility of friction skin from a single individual during the entire duration of 
capecitabine chemotherapy, beginning on the first day of treatment and ending 
approximately sixty days following the cessation of treatment. The study participant was 
initially diagnosed in May 2007 with invasive ductile carcinoma of the breast with a 
triple negative phenotype. Initial treatment consisted of three rounds each of 
Adriamycin/Cytoxan (administered together) and Taxol_from July 2007 through 
November 2007. In November 2008, the study participant was diagnosed with metastatic 
breast cancer in the bones. Radiation and treatment with capecitabine (six rounds) 
showed success in clearing detectible cancerous activity according to positron emission 
tomography (PET) scans in May 2009. After a follow-up in August 2009 PET scans 
detected an increase in cancerous activity. The participant resumed capecitabine 
treatment on August 27, 2009, marking the first day of this case study evaluation. 
Informed consent was obtained prior to the study commencement. The treatment 
regimen of capecitabine consisted of multiple three week long cycles. During each cycle 
the participant is prescribed to take 2500mg/m2 per day taken in two doses with a 12 hour 
lapse between each dose for two weeks and then no medication being prescribed for the 
third week. The duration of the treatment was contingent upon the therapeutic success 
and lasted a total of 188 days. The total duration of the study lasted 253 days. 
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Recording Medium 
Multiple methods of capture were used in an attempt to record the friction ridge 
skin throughout the duration of the study to include digital imaging, powder, ink, and 
livescan. The digital imaging technique consisted of obtaining digital images under 
white light using a Nikon D2XS digital camera with and without black powder coating 
the friction skin for contrast purposes. The purpose of the general photography was two-
fold: 1) To capture any friction ridge detail present through the use of traditional 
photography, and 2) to show the redness, irritation, and peeling of the skin as a·result of 
the HFS. The powder technique consisted of coating the friction skin with a thin layer of 
traditional fingerprint powder. The powder was then removed from the ridges of the 
fingers through the use of the adhesive side of a white mailing label. This label was then 
placed adhesive side down, onto a clear piece of acetate similar to that of a fingerprint 
card. This technique is commonly known as the powder/label technique and is utilized 
when obtaining post mortem record fingerprints of deceased individuals. This technique 
has been shown to capture the faintest of friction ridge details from the most difficult of 
surfaces. The traditional ink method consisted of coating the friction skin with a thin 
layer of standard printers ink and rolling the fingers onto a white fingerprint card. This 
technique was incorporated as it is the most common method of obtaining record finger 
and palm prints in today's criminal justice system. While this technique is common, it 
typically does not provide as good detail as the post mortem technique previously 
mentioned. Two sets of record fingerprints were obtained utilizing this technique on a 
regular basis. In addition to the traditional inked sets of prints, a set of ten rolled prints 
strictly from the left index finger (study participant is left handed) on a standard white 
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8.5" by 11" sheet of printer paper were obtained. The set of ten were obtained in an 
attempt to ensure the highest quality impression was obtained despite possible movement 
or smudging. An additional set of record fingerprints utilizing the traditional ten-print 
card and ink were obtained following the application of ID-Enhancer Spray in order to 
evaluate the effectiveness of this product to determine its effectiveness for increasing the 
quality of the impressions. Limited access to Live Scan technology was available; 
however, several attempts were made which consisted of digitally recording the friction 
skin and saving the images according to the Electronic Fingerprint Transmission 
Specification (EFTS) using a Crossmatch Technologies ID500 livescan system. 
The Procedure 
A baseline set of record fingerprints were obtained at the beginning of the study 
on the first day of capecitabine treatment. This set of record fingerprints serves as the 
basis for which the quality of all friction skin should not surpass during the duration of 
the study. Throughout the course of the study, record fingerprints were obtained using 
the traditional ink technique on a weekly basis. In additional to the weekly traditional ink 
technique, one set of record fingerprints were obtained upon treatment with the ID 
Enhancer Spray. Approximately every four weeks throughout the course of the study 
additional record fingerprints were obtained using digital imaging and powder 
techniques. Record fingerprints using livescan were obtained on three separate occasions 
throughout the study due to the lack of availability to live scan equipment. 
The quality of all record fingerprints were evaluated using the AFIX Tracker 
Automated Fingerprint Identification System (AFIS) automated quantitative scoring 
system with no digital enhancements. The AFIX Tracker ratings were used to evaluate 
the quality of the impressions (reproducibility of the friction skin) over the course of 
treatment, as well as, to facilitate a comparison of the effectiveness of the various 
recording techniques and the ability of ID Enhancer to increase the quality of the 
impressions coming from damaged areas of friction skin. 
A statistical analysis was carried out in an attempt to determine any statistical 
significance among the quality of the friction ridge skin recorded before and during 
capecitabine induced HFS (actual effect); the quality of the friction ridge skin recorded 
before and after capecitabine induced HFS (overall effect); the success amongst the 
methods used for capturing friction ridge skin (which technique is better) and; whether 
the ID Enhancer played a significant role in the enhancement of any friction ridge skin 
captured throughout any point in the study. 
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CHAPTERIV 
ANALYSIS OF DATA 
Reliability Measurements 
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Observations of the quality of the friction skin using the AFIX Tracker throughout 
the course of this study indicate that the average quality score, at 95% confidence, for the 
fifty impressions on each the first and last day of the study using the ink method was 55.0 
+/- 5.1 and 49.8 +/- 7.8, respectively. The average quality score on the first day was 
considered the baseline reference score. The average quality over the course of the 
entire study using the ink method with and without the application of ID Enhancer was 
43.1 +/- 3.4 and 41.6 +/- 1.6, respectively. The average quality score over the course of 
the entire study using the powder method was 42.4 +/- 10.7 and the average quality score 
on the three occasions over the course of the study in which the friction skin was 
recorded using livescan was 37.3 +/- 7.6. These results suggest that the powder method 
as well as the ink method with the application of ID Enhancer spray did appear to result 
in increased levels of quality compared to the other methods while the livescan method 
consistently yielded the least quality impressions. These differences between the two 
methods yielding the highest and lowest quality impressions (ink method with the 
application of ID Enhancer spray and the livescan method), however, did not differ to a 
statistically significant degree (p=0.44) assuming a significance level of p=0.05 using the 
student' s t-test. Under this assumption of statistical significance, in order for one method 
to be considered as out-performing the other based on the quality of the impressions 
resulting from that method, the 'p' value would need to be less than 0.05. 
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The average quality of the friction skin rapidly decreased by 32% between 
approximately 36 to 48 days into the study. The quality of the friction skin remained at 
the decreased level throughout the course of treatment until approximately 30 days 
following the cessation of treatment at 218 days into the study at which point the quality 
of the friction skin began to rapidly improve returning approximately to the baseline level 
that was established on the first day of treatment (Tables 1 and 2). 
Table 1 
Friction Ridge Skin Quality Throughout Duration of Study 
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Graph representing the quality of the friction ridge skin impressions using the AFIX Tracker Automated Quality Score during the 
course of the 253 day evaluation. The graph represents the quality of the impressions recorded using the ink method. 
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Table 2 
Friction Ridge Skin Quality Throughout Duration of Study with Time Explanation 
so ~----
10 -1-- ---
60 ti;;;;;;;;;+-"9---= 
so ..,__..__ __ _ 
40 +------
30 +-- ----, 
20 -1-----
10 +------, 
Quality of Friction Ride• Skin lmprealons (95" Confidence) 
24 
0 25 so 75 100 125 150 175 200 225 250 
Graph representing the same information in Table I, except with the addition of sectioned time periods. The section labeled "A" 
indicates the 36 day time period prior to the decline in friction ridge skin quality due to the onset of HFS. The section labeled "B" 
indicates the sustained time period in which the participant continued normal treatment with capecitabine. The section labeled "C" 
indicates the 30 days time period in which the participant had ceased treatment, but the quality of the friction skin remained at the 
decreased quality state. The section labeled "D" indicates the time period in which the quality of the friction ridge skin rapidly 
improved (30 days post cessation of treatment). 
Discussion of Results 
The results of this study indicate that the decrease in the quality of the friction 
skin is directly related to the capecitabine treatment. The intervals of significant decrease 
and increase observed in the quality of the friction skin is consistent with previous 
literature suggesting that full keratinocyte maturation lasts approximately 30_ to 40 days 
for the keratinocytes to migrate from the basal layer to the outer most layer of the 
epidermis (Stratum Comeum) (Wertheim K. M., 2002). 
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Figure 9. Friction skin of the study participant on the 89th day of the study 
Figure JO. Friction skin of the study participant on the 89th day of the study 
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Because only those keratinocytes that are present on the outer most layer of the 
eptdermis were observed in this study, this delay in observed decrease and increase of 
quality thus supports the literature suggesting that the pathogenesis of capecitabine 
induced HFS is the result of the exposure of the basal layer of keratinocytes to the 
cytotoxic effects of 5-FU and its metabolites thus preventing proper basal keratinocyte 
proliferation. Traditional symptoms of capecitabine induced HFS .were both reported by 
the participant and observed throughout the course of treatment, which include general 
discomfort, mild to severe pain in the palms of the hands and soles of the feet, erythema, 
and pronounced desquamation which is illustrated in Figures 9, 10, and 11. The pain 
experienced by the study participant as a result of the HFS was mitigated through 
treatment with various pain medications as prescribed by the physician, which included 
Lyrica and Gabapentin. These pain medications were prescribed around the 130 day 
mark which is consistent with the graph in Table 2. As pain increased, the study 
participant was less likely to engage in normal daily activities. As a result, the severity of 
the HFS lessened and is represented as a short increase in friction ridge skin quality prior 
to the 130 day mark. However, as pain medication was prescribed, the study participant 
was able to carry on with regular daily activities. The constant abrasive forces and 
contact with the palmar side of the hand during routine activities resulted in an increased 
severity of HFS primarily due to the study participants inability to detect discomfort due 
to pain medication. The severe HFS was a result of decreased friction skin quality as 
depicted in the 175 to 180 day mark in Table 2. The particular time period also represents 
one of the lowest points in friction skin quality and the cessation of the capecitabine 
treatment. The 220 day time period clearly depicts the point where new friction skin is 
7 
27 
given the opportunity to regenerate 30 days after the cessation of capecitabine treatment 
and is the cornerstone of establishing the permanency of friction ridge skin after 
biochemical manipulation/alteration. 
Figure I 1. Friction skin on the foot of the study participant on the 106th day of the study. 
Once the quality of the friction skin improved and returned to the baseline level, 
approximately 65 days following the cessation of treatment, it was noted that the 
arrangement of the friction skin characteristics were not altered in their location, 
orientation, or relative spatial relationship. This observation again supports the 
persistency of the arrangements of the friction skin characteristics despite this temporary 
toxic exposure to the basal keratinocytes throughout the treatment (Figure 12). The 
middle image in Figure 12 demonstrates the poor quality of the friction skin impression 
obtained using the ink method while undergoing treatment of capecitabine and 
experiencing HFS. The poor quality of the friction skin impression in Figure 12 (middle) 
illustrates the severity of which capecitabine induced HFS can interfere with the friction 
ridge skin examination process. 
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Figure 12 - Each image represents the appearance of the friction skin of the left index 
of the study participant recorded using the ink method on (left) the first day of the 
study, (middle) the 841h day of the study, and (right) the 253rd (last) day of the study. 
Note that the arrangement of the friction ridges and ridge characteristics were not 
altered between the first and last days of the study (left and right respectively) despite 
the temporary toxicity to the keratinocytes. The middle image demonstrates the poor 
quality of the friction skin impression obtained using the ink method while undergoing 
treatment of capecitabine and experiencing HFS. 
CHAPTERV 
SUMMARY 
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This study focused on evaluating the negative effects that capacitabine induced 
HFS has on the quality of friction skin for forensic and other comparative purposes. The 
results of this study show that capecitabine induced HFS caused a significant decrease in 
the quality of the friction skin which may impair the ability to positively identify an 
individual using friction skin impressions alone. The results of this study support 
previous literature suggesting that capecitabine induced HFS, which is responsible for the 
negative effects to the friction skin, is caused by the exposure of the basal keratinocytes 
to the cytotoxic effects of 5-FU and its metabolites thus preventing proper basal 
keratinocyte proliferation. Despite this temporary toxicity to the basal keratinocytes, 
persistency of friction ridge characteristics was noted during the former and latter 
portions of the study. The results obtained from this study provide insight into the effects 
that capecitabine induced HFS has on the quality of friction skin from a forensic or other 
comparative perspective; however, this study was limited to evaluating the effects to the 
friction skin on one individual during the course of capecitabine treatment. Further 
research is needed to more fully understand the potential effects that capecitabine 
treatment, with various dosage regimens, may have on other individuals as well as the 
effects other methods of chemotherapy may have on the quality of friction skin and to 
what level of severity. 
Of major concern for those within the criminal justice community is the ability to 
temporarily obliterate ones identity via the oral ingestion of several pills. 
Communications with research oncologists and law enforcement officials indicate that 
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capecitabine is not a very common drug of choice on the street simply due to its overall 
effects. Street drugs are typically focused around obtaining a euphoric high or an 
adrenaline rush with almost negligent consequences depending on the amount and 
frequency of ingestion. These drugs typically do not cause as much discomfort as that 
which is attributed to capecitabine. Individuals looking to partake in common street drugs 
in a social environment would typically shy away from those causing blisters, ulceration, 
and desquamation. However, those individual not necessarily after the social high and are 
in need of concealing their identity for short periods of time for one reason or another 
may consider the capecitabine route if available. Rather than undergoing the painstaking 
techniques previously mentioned in this study such as the Z-Flap incision, acid etching, 
and transplantation; popping a few pills with the occasional diarrhea and skin peeling 
side effects doesn't sound like such a bad idea. 
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